PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
SCHOFIELD, Wis., July 2, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.
PuraMed BioScience has updated that as of June 30, 2013, the current common shares issued and outstanding was 42,610,297.
In addition, the company plans to provide monthly updates on current share structure to provide for increased transparency, and will provide these updates through their official social networking site on Twitter at http://twitter.com/PuraMed
Russ Mitchell, the Chairman and CEO of PuraMed BioScience, commented in a recent interview that with nearly 60 million Americans suffering from migraines the revenue potential for LipiGesic™ M, their over-the-counter migraine relief product, could generate over $50 million annually.
- Revenue Potential for LipiGesic M Could Exceed $50 Million
- Expanding Retail Chain-Store Distribution
- Potential Patent Portfolio Acquisition Worth Millions
- Market Capitalization Currently under $1 Million
Mr. Mitchell also discussed expanding distribution for their over-the-counter migraine pain reliever product, which is currently in such stores as Walgreen's and CVS/pharmacy, and plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
To access the online interview, please visit http://www.wallstreetnewscast.com/profile/pmbs.html
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
South Street Media, Inc
Phone: (917) 937-8968
SOURCE PuraMed BioScience, Inc.